FEMY - Femasys Momentum continues after Two Announcements the Week

2023-09-29 07:45:41 ET

(24/7 MARKET NEWS) – Femasys Inc. (NASDAQ: FEMY) announced, after Tuesday’s market close, that it received 510(k) Clearance from the US Food and Drug Administration for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube, and followed up by reporting, yesterday, that it activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc.

Femasys is trading at $$1.66, up $0.14 (+9.21%), on 445.35K premarket shares traded.

Its 52-week range is $0.2479 to 1.79. It hit a new 52-week high yesterday and is well positioned to eclipse that today.

24/7 MARKET NEWS, INC …

The post Femasys Momentum continues after Two Announcements the Week appeared first on 24/7 Market News .

For further details see: